Search - tctmd.com

Displaying 741 - 760 of 970

Sort: Relevancy | Date

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Philippe Gabriel Steg

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Fausto Feres

September 14, 2014

Presentation TCT 2014

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

Time to Move to 3-6 Months Even in ACS!

Presenter: Marco Valgimigli

September 14, 2014

Presentation TCT 2014

Definitely Not the Data are Clear!

Presenter: Germano Di Sciascio

September 14, 2014

Presentation TCT 2014

Definitely the Data are Clear!

Presenter: E. Magnus Ohman

September 14, 2014

Presentation TCT 2014

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: David J. Moliterno, E. Magnus Ohman, Duane S. Pinto, Michael Lipinski

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Rod H. Stables

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Gregg W. Stone

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Stefanie Schüpke

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Roxana Mehran

September 14, 2014

Presentation TCT 2014

State of the (Drug-Eluting) Stent: World-Wide Usage, New Perspectives in Stable CAD, and Remaining Challenges

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

Presentation TCT 2014

Vorapaxar is Safe and Effective and Has an Important Role to Play in Patients with CAD

Presenter: Jessica L. Mega, Daniel I. Simon, Michelle O'Donoghue

September 14, 2014

Presentation TCT 2014

How Did I Treat This Patient?

Presenter: Eric A. Cohen, Dean J. Kereiakes, Samer Mansour

September 14, 2014

Presentation TCT 2014

How Would I Treat This Patient?

Presenter: Eric A. Cohen, Dean J. Kereiakes, Stuart Watkins

September 14, 2014

Presentation TCT 2014

Case #3. Multivessel Disease in a Stable CAD Patient

Presenter: Eric A. Cohen, Dean J. Kereiakes, Samer Mansour

September 14, 2014

Advertisement

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Time to Move to 3-6 Months Even in ACS!

Definitely Not the Data are Clear!

Definitely the Data are Clear!

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

State of the (Drug-Eluting) Stent: World-Wide Usage, New Perspectives in Stable CAD, and Remaining Challenges

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Vorapaxar is Safe and Effective and Has an Important Role to Play in Patients with CAD

How Did I Treat This Patient?

How Would I Treat This Patient?

Case #3. Multivessel Disease in a Stable CAD Patient

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content